

238 ZZN	मैथोक्सी एसीटायलफेंटनाइल		2-मैथोक्सी-एन-फेनाइल-एन-[1-(2- फेनाइलीथिल) पीपरीडीन -4-यल] एसिटामाइड	0.005 ग्राम	0.1 ग्राम;
238 ZZO	साइक्लोपरोफेंटनाइल		एन-फेनाइल- एन -[1-(2-फेनाइल) पीपरीडीन-4-यल] साइक्लोपरोपेन कॉरबोएक्सामिड	0.005 ग्राम	0.1 ग्राम”.

[फा. सं. एन-13/1/2019-एनसी. II]

दिनेश बौध्द, निदेशक

टिप्पणी: प्रधान अधिसूचना जिसे का.आ.1055 (अ), दिनांक 19 अक्टूबर, 2001 के तहत भारत के राजपत्र, असाधारण, भाग II, खण्ड 3, उपखण्ड (ii) में प्रकाशित किया गया था और इसमें बाद में का.आ.2941 (अ), दिनांक 18 नवम्बर, 2009, का.आ.1430 (अ), दिनांक 21 जून, 2011, का.आ.375 (अ) दिनांक 5 फरवरी, 2015, का.आ. 2375(अ), दिनांक 12 जुलाई, 2016, का.आ.384 (अ), दिनांक 2 मई, 2017, का.आ. 822(अ), दिनांक 27 फरवरी, 2018, का.आ.1762(अ), दिनांक 26 अप्रैल, 2018, का.आ.1351(अ), दिनांक 13 मार्च, 2019 के अंतर्गत संशोधन किया गया है।

NOTIFICATION

New Delhi, the 23rd March, 2021

S.O. 1276(E).—In exercise of the powers conferred by clauses (viiia) and (xxiiia) of section 2 of the Narcotic Drugs and Psychotropic Substances Act, 1985 (61 of 1985), the Central Government hereby makes the following further amendments in the notification of the Government of India, Ministry of Finance, Department of Revenue, published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii) *vide* number S.O. 1055 (E), dated the 19th October, 2001, namely: -

In the said notification, in the Table, after serial number 238 ZI, 238 ZJ, 238 ZK, 238 ZL, 238 ZM, 238 ZN, 238 ZO, 238 ZP, 238ZQ, 238ZR, 238ZS and 238 ZT and the entries relating thereto, the following serial numbers and entries shall be substituted, namely: -

SI. No.	Name of Narcotic Drug and Psychotropic Substance (International non-proprietary name (INN))	Other non-proprietary names	Chemical name	Small Quantity (in gm.)	Commercial Quantity (in gm./kg.)
“238ZI	Carfentanil		Methyl 1-(2-phenylethyl)-4-[phenyl(propionyl)amino]piperidine-4-carboxylate	0.00005 gm	0.001 gm;
238 ZJ	Ocfentanil		N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide	0.00217 gm	0.0434 gm;
238 ZK	Furanylfentanyl		N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide	0.02 gm	1 gm;
238 ZL	Acryloylfentanyl	Acrylfentan-yl	N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide	0.0025 gm	0.125 gm;

238ZM	4-Fluoroisobutyrfentanyl	4-FIBF, pFIBF	N-(4-Fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propenamide;	0.03 gm	1.5 gm;
238 ZN	Tetrahydrofuranylfentanyl	THF	N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]oxolane-2-carboxamide	0.005 gm	0.1 gm;
238 ZO		AB-CHMINACA	N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide	0.05 gm	2.5 gm;
238 ZP		5F-ADB (5F-MDMB-PINACA)	Methyl(2S)-2-{1-(5-fluorophenyl)-1H-indazole-3-carboxylamino}-3,3-dimethylbutanoate	0.005 gm	0.25 gm;
238 ZQ		AB-PINACA	N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide	0.0178 gm	0.892 gm;
238 ZR		UR-144	(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	0.05 gm	2.5 gm;
238 ZS		5F-PB-22	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	0.1 gm	5.0 gm;
238 ZT	4-Fluoroamphetamine	4-FA	1-(4-Fluorophenyl) propan-2-amine	2 gm	50 gm;
238ZU		AB-FUBINACA	N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]indazole-3-carboxamide	0.025 gm	1.25 gm;
238ZV		5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA)	Methyl 2-([1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl)amino)-3-methylbutanoate	0.0027 gm	0.135 gm;
238ZW		5F-MDMB-PICA (5F-MDMB-2201)	Methyl(S)-2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate	0.0050 gm	0.25 gm;
238ZX		4F-MDMB-BINACA	Methyl(S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate	0.0050 gm	0.25 gm;
238ZY	4-CMC (4-chloromethcathinone)	clephedrone	1-(4-chlorophenyl)-2-(methylamino)-1-propanone	5.0 gm	250 gm;
238ZZ		N-ethylhexedrone	2-(Ethylamino)-1-phenyl-1-hexanone	1.0 gm	50 gm;
238ZZA		alpha-PHP	(RS)-1-Phenyl-2-(pyrrolidine-1-yl)hexan-1-one	0.1 gm	5.0 gm;

238ZZB		flualprazolam	8-Chloro-6-(2-fluorophenyl)-1-methyl-4benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepime	0.0125 gm	0.625 gm;
238ZZC	Etizolam		4-(2-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3a][1,4]diazepine	0.05 gm	2.5 gm;
238ZZD		DOC	4-Chloro-2,5-dimethoxyamfetamine	0.15 gm	7.5 gm;
238ZZE		ADB-FUBINACA	N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1Hindazole-3-carboxamide	0.01 gm	0.5 gm;
238ZZF		FUB-AMB, MMBFUBINACA, AMBFUBINACA	Methyl(2S)-2-({1-[4-fluorophenyl]methyl-1Hindazole-3-carbonyl}amino)-3-methylbutanoate	0.01 gm	0.5 gm;
238ZZG		CUMYL-4CNBINACA	1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1Hindazole-3-carboxamide	0.01 gm	0.5 gm;
238ZZH		ADB-CHMINACA, MAB-CHMINACA	N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1Hindazole-3-carboxamide	0.005 gm	0.25 gm;
238ZZI		N-ethylnorpentylone	1-(2H-1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one	0.1 gm	5 gm;
238ZZJ	Crotonylfentanyl		(2E)-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]but-2-enamide	0.014 gm	0.28 gm;
238ZZK	Valeryl fentanyl		N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide	0.40 gm	8.0 gm;
238ZZL	Parafluorobutyrylfentanyl		N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]butanamide	0.005 gm	0.1 gm;
238ZZM	Ortho-Fluorofentanyl		N-(2-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide	0.005 gm	0.1 gm;
238ZZN	Methoxyacetyl fentanyl		2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide	0.005 gm	0.1 gm;
238ZZO	Cyclopropylfentanyl		N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropane carboxamide	0.005 gm	0.1 gm”.

[F. No. N-13/1/2019-NC. II]

DINESH BOUDDH, Director

Note : The principal notification was published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (ii), *vide* number S.O. 1055 (E), dated the 19th October, 2001 and subsequently amended *vide* numbers S.O. 2941 (E), dated the 18th November, 2009, S.O. 1430 (E), dated the 21st June, 2011, S.O. 375 (E) dated the 5th February, 2015, S. O. 2375(E), dated the 12th July, 2016, S.O. 384 (E), dated the 2nd May, 2017, S.O. 822(E), dated the 27th February, 2018, S.O. 1762(E), dated the 26th April, 2018 and S.O. 1351(E), dated the 13th March, 2019